Your browser doesn't support javascript.
loading
Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery.
Ewart, Lorna; Dehne, Eva-Maria; Fabre, Kristin; Gibbs, Susan; Hickman, James; Hornberg, Ellinor; Ingelman-Sundberg, Magnus; Jang, Kyung-Jin; Jones, David R; Lauschke, Volker M; Marx, Uwe; Mettetal, Jerome T; Pointon, Amy; Williams, Dominic; Zimmermann, Wolfram-Hubertus; Newham, Peter.
Afiliación
  • Ewart L; Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca, Cambridge CB4 0WG, United Kingdom; email: lorna.ewart@astrazeneca.com.
  • Dehne EM; TissUse, Berlin 13347, Germany.
  • Fabre K; Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca, Waltham, Massachusetts 02451, USA.
  • Gibbs S; Department of Dermatology, VU University Medical Center, 1081 HZ Amsterdam, The Netherlands.
  • Hickman J; Department of Oral Cell Biology, Academic Center for Dentistry Amsterdam, University of Amsterdam and VU University, 1081 LA Amsterdam, The Netherlands.
  • Hornberg E; NanoScience Technology Center, University of Central Florida, Orlando, Florida 32826, USA.
  • Ingelman-Sundberg M; Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca, 431 83 Mölndal, Sweden.
  • Jang KJ; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, 171 77 Stockholm, Sweden.
  • Jones DR; Emulate Inc., Boston, Massachusetts 02210, USA.
  • Lauschke VM; Medicines & Healthcare Products Regulatory Agency, London SW1W 9SZ, United Kingdom.
  • Marx U; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, 171 77 Stockholm, Sweden.
  • Mettetal JT; TissUse, Berlin 13347, Germany.
  • Pointon A; Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca, Waltham, Massachusetts 02451, USA.
  • Williams D; Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca, Cambridge CB4 0WG, United Kingdom; email: lorna.ewart@astrazeneca.com.
  • Zimmermann WH; Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca, Cambridge CB4 0WG, United Kingdom; email: lorna.ewart@astrazeneca.com.
  • Newham P; Institute of Pharmacology and Toxicology, University Medical Center Goettingen, Goettingen 37075, Germany.
Annu Rev Pharmacol Toxicol ; 58: 65-82, 2018 01 06.
Article en En | MEDLINE | ID: mdl-29029591
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Descubrimiento de Drogas Tipo de estudio: Screening_studies Límite: Animals / Humans Idioma: En Revista: Annu Rev Pharmacol Toxicol Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Descubrimiento de Drogas Tipo de estudio: Screening_studies Límite: Animals / Humans Idioma: En Revista: Annu Rev Pharmacol Toxicol Año: 2018 Tipo del documento: Article